Feasibility study of postoperative adjuvant carboplatin plus nab-paclitaxel for complete resected pathological stage II/IIIA non-small cell lung cancer

Feasibility study of postoperative adjuvant carboplatin plus nab-paclitaxel for complete resected pathological stage II/IIIA non-small cell lung cancer - FASTnab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011225

Enrollment

Registered

2013-07-19

Start date

2013-07-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

completely resected pathological stage II/IIIA non-small cell lung cancer

Interventions

carboplatin plus nab-paclitaxel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1, pathologically confirmed stage II/III non-small cell lung cancer 2, patients who underwent at least lobectomy with selective or systematic lymph nodal dissection 3, patients with complete resection of non-small cell lung cancer

Exclusion criteria

Exclusion criteria: 1.History of drug hypersensitivity 2.Serious surgical or non-surgical complications 3.Active secondary cancer. 4.Patient to whom primary doctor judjed inadequate to register.

Design outcomes

Primary

Measure	Time frame
Completion rate of scheduled adjuvant chemotherapy	—

Secondary

Measure	Time frame
Relative dose intensity, Disease-free survival, Overall survival, Incidence and grade of adverse events	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026